About: Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
Creator	Manabe, Atsushi Chida-Nagai, Ayako Izumi, Gaku Takeda, Atsuhito Taniguchi, Kota Yamazawa, Hirokuni Fujimoto, · Masaki, · Sagawa, · Sasaki, · Takao Tsujioka, ·
Source	PMC
abstract	Congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) is one of the major complications in patients with CHD. A timely closure of the left-to-right shunt will generally result in the normalization of the pulmonary hemodynamics, but a few patients have severe prognosis in their early childhood. We hypothesized that wide-ranging pathological mechanism in PAH could elucidate the clinical state of severe CHD-PAH. Using electronic medical records, we retrospectively analyzed six infants with severe CHD-PAH who had treatment-resistant PH. All patients were born with congenital malformation syndrome. After starting on a pulmonary vasodilator, five of the six patients developed complications including pulmonary edema and interstitial lung disease (ILD), and four patients had alveolar hemorrhage. After steroid therapy, the clinical condition improved in four patients, but two patients died. The autopsy findings in one of the deceased patients indicated the presence of recurrent alveolar hemorrhage, pulmonary venous hypertension, ILD, and PAH. Based on the clinical course of these CHD-PAH in patients and the literature, CHD-PAH can occur with pulmonary vascular obstructive disease (PVOD)/pulmonary capillary hemangiomatosis (PCH), ILD, and/or alveolar hemorrhage. The severity of CHD-PAH may depend on a genetic disorder, respiratory infection, and upper airway stenosis. Additionally, pulmonary vasodilators may be involved in the development of PVOD/PCH and ILD. When patients with CHD-PAH show unexpected deterioration, clinicians should consider complications associated with PVOD/PCH and/or pulmonary disease. In addition, the choice of upfront combination therapy for pediatric patients with CHD-PAH should be selected carefully.
has issue date	2020-04-13(xsd:dateTime)
bibo:doi	10.1007/s00380-020-01604-1
bibo:pmid	32285188
has license	no-cc
sha1sum (hex)	1f838b2aeb6ba6074bd3409d423e0af1b6dea73d
schema:url	https://doi.org/10.1007/s00380-020-01604-1
resource representing a document's title	Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
has PubMed Central identifier	PMC7152743
has PubMed identifier	32285188
schema:publication	Heart Vessels
resource representing a document's body	covid:1f838b2aeb6ba6074bd3409d423e0af1b6dea73d#body_text
is schema:about of	named entity 'pulmonary arterial hypertension' named entity 'pediatric' named entity 'ILD' named entity 'pulmonary disease' named entity 'selected' named entity 'patients' named entity 'complications' named entity 'developed' named entity 'vasodilator' named entity 'upfront' named entity 'arterial' named entity 'TREATMENT' named entity 'PULMONARY' named entity 'THESE' named entity 'GENETIC DISORDER' named entity 'MECHANISM' named entity 'PATIENTS' named entity 'STATE' named entity 'AUTOPSY' named entity 'PULMONARY VENOUS HYPERTENSION' named entity 'RESULT' named entity 'retrospectively' named entity 'patients' named entity 'depend' named entity 'disease' named entity 'treatment-resistant' named entity 'hemorrhage' named entity 'heart' named entity 'patients' named entity 'result' named entity 'severe' named entity 'died' named entity 'hemodynamics' named entity 'closure' named entity 'stenosis' named entity 'timely' named entity 'PAH' named entity 'PAH' named entity 'autopsy' named entity 'PAH' named entity 'PAH' named entity 'upper airway' named entity 'genetic disorder' named entity 'hemorrhage' named entity 'alveolar' named entity 'pulmonary capillary hemangiomatosis' named entity 'ILD' named entity 'ILD' named entity 'PVOD' named entity 'hemorrhage' named entity 'steroid' named entity 'mechanism' named entity 'venous hypertension' named entity 'PAH' named entity 'PAH' named entity 'PCH' named entity 'atrioventricular septal defect' named entity 'poor feeding' named entity 'chromosomal' named entity 'Hokkaido University' named entity 'bullae' named entity 'nitric oxide' named entity 'PVOD' named entity 'chest X-ray' named entity 'lung' named entity 'pulmonary artery banding' named entity 'upper respiratory tract' named entity 'lung' named entity 'dysplasia' named entity 'hypoplastic' named entity 'pulmonary vessels'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software